Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,754.40
(
0.14%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.55
(
1.07%
)
Bitcoin
71,114.00
(
1.74%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 195231

Tuesday, 11/15/2016 5:05:34 PM

Tuesday, November 15, 2016 5:05:34 PM

Post# of 257262
AMGN/AGN submit 351(k) application for Avastin FoB:

http://finance.yahoo.com/news/amgen-allergan-submit-biosimilar-biologics-210000281.html

AGN retained its stake of the AMGN FoB partnership when selling its generic-drug business to TEVA. The AMGN-AGN FoB collaboration was announced in 2011 (#msg-70097496); the company now known as AGN was originally Watson Pharmaceuticals (before several rounds of mergers and acquisitions).

AMGN and AGN are also collaborating on FoBs for Rituxan, Herceptin, and Erbitux, while AMGN is developing FoBs for Humira and Remicade on its own.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now